Stock Code: 301033 Stock Abbreviation: Medprin Listing Venue: Shenzhen Stock Exchange
[Chart: Medprin logo]
Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
Abstract of the Report on the Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Party Transactions (Draft) (Registration Version) (Revised Version)
| Item | Name |
|---|---|
| Counterparties for asset purchase | Guangzhou Zexin Medical Technology Co., Ltd. |
| Guangzhou Yichuangxiang Investment Partnership (Limited Partnership) | |
| Guangzhou Huangpu Pioneer Medical Venture Capital Fund Partnership (Limited Partnership) | |
| Guangdong Jike Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) | |
| Hu Ganwei | |
| Guangzhou Fuheng Investment Co., Ltd. | |
| Yuan Ziyang | |
| Guangzhou Industrial Investment Biomedical and Health Special Mother Fund Partnership (Limited Partnership) | |
| Guangzhou Industrial Investment Productivity Venture Capital Partnership (Limited Partnership) | |
| Guangzhou Youjiu Equity Investment Center (Limited Partnership) | |
| Subscriber for supporting funds | Guangzhou Yijian Medical Investment Co., Ltd. |
Independent Financial Advisor
Huatai United Securities Co., Ltd.
Signing Date: July 2026
Statement
The terms or abbreviations used in this section have the same meanings as those defined in the "Definitions" section of this report abstract.
I. Statement of the Listed Company
The Company and all its directors and senior management guarantee that the Company discloses information in a timely and fair manner, and ensure the authenticity, accuracy, and completeness of the contents of this report abstract, with no false records, misleading statements, or major omissions. They guarantee the authenticity and reasonableness of the relevant data cited in this report abstract and assume corresponding legal liability for the authenticity, accuracy, and completeness of the provided information.
If the information disclosed or provided in this transaction is suspected of containing false records, misleading statements, or major omissions, and is subject to case investigation by judicial authorities or the China Securities Regulatory Commission (CSRC), the parties involved shall not transfer the shares held in the listed company until the investigation conclusion is formed. They shall submit a written application for suspension of transfer and their stock account to the board of directors of the listed company within two trading days of receiving the notice of investigation, and the board of directors shall apply for a lock-up on their behalf to the stock exchange and the securities registration and clearing institution. If the application is not submitted within two trading days, the board of directors is authorized to verify and directly submit the identity and account information of the individual or entity to the stock exchange and the securities registration and clearing institution to apply for a lock-up. If the board of directors fails to submit such information, the stock exchange and the securities registration and clearing institution are authorized to lock the relevant shares directly. If the investigation concludes that there are illegal or non-compliant circumstances, the individual or entity promises that the locked shares will be voluntarily used for relevant investor compensation arrangements.
Any decision or opinion made by the CSRC or the Shenzhen Stock Exchange regarding this transaction does not represent a substantive judgment or guarantee of the value of the Company's shares or investor returns.
In accordance with the Securities Law and other relevant laws and regulations, after the completion of this transaction, the Company is responsible for its own operations and earnings changes, and investors are responsible for the investment risks arising from such changes. When evaluating this transaction, investors should carefully consider the risk factors disclosed in this report abstract in addition to the content of this report abstract and relevant documents disclosed simultaneously. If investors have any questions regarding this report abstract, they should consult their stock broker, lawyer, accountant, or other professional advisor.